Pre-made Apolizumab benchmark antibody (Whole mAb, anti-HLA-DRB/HLA-DRB1 therapeutic antibody, Anti-DRB1/SS1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-736

Anti-HLA-DRB/HLA-DRB1 therapeutic antibody (Pre-made Apolizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 25 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3] There are no current clinical trials into its use.[4]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-736-1mg 1mg 3090
GMP-Bios-INN-736-10mg 10mg Inquiry
GMP-Bios-INN-736-100mg 100mg Inquiry
GMP-Bios-INN-736-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Apolizumab Biosimilar, Whole Mab, Anti-HLA-DRB/HLA-DRB1 Antibody: Anti-DRB1/SS1 therapeutic antibody
INN Name Apolizumab
TargetHLA-DRB/HLA-DRB1
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesPDL (Protein Design Labs) BioPharma (Fremont CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0